SEC Filings
Viasat Sales Rise 3% — But Defense Growth Cannot Prevent A Wider Quarterly Loss
Communication services shrank, while Viasat now expects roughly flat full-year adjusted EBITDA and more than $225 million in free cash flow.
SEC Filings
Communication services shrank, while Viasat now expects roughly flat full-year adjusted EBITDA and more than $225 million in free cash flow.
SEC Filings
AI and servers are now about 20% of revenue, but traditional PC weakness is expected to outweigh their growth within Computing.
SEC Filings
AvePoint raised its recurring-contract outlook as cash generation increased and its AI governance platform expanded.
SEC Filings
SkyWater added $83.5 million in quarterly sales, while IonQ raised its annual revenue outlook to $505 million–$515 million.
SEC Filings
TRUTAKNA's rollout brought approximately 700 patient start forms, while Vera seeks full FDA approval based on kidney-function data.
SEC Filings
The biotech kept its cash-use forecast unchanged and expects an Alzheimer's trial readout in the first half of 2027.
SEC Filings
The drug developer expects funding to last into the second half of 2028, with a colorectal-cancer trial update due in January 2027.
SEC Filings
The cardiac-surgery company narrowed its full-year outlook as it prepares to launch NEXUS in the U.S. in January 2027.
SEC Filings
The AI data-services company raised its annual growth outlook as new customer wins offset a program wind-down.
SEC Filings
The drug developer holds $945.7 million in cash and short-term investments and plans to present initial autoimmune-treatment data Monday.
SEC Filings
Sana expects funding into mid-2027, while higher manufacturing and laboratory costs widened its quarterly adjusted loss.
SEC Filings
The departure comes at a diagnostics business whose lung-testing operation generated $79.2 million in revenue in 2025.